Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC (Cisplatin, CPT-11, Celecoxib) with Radiation and Surgery for Esophageal Cancer
NCT00137852Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2002
- Primary completion
- Aug 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in esophageal cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response rate of combination of chemotherapy, radiation therapy and surgery. Started Jan 2002; status: completed.
02
Drugs
celecoxib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00137852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137852.